Fibrogen’s roxadustat has its first European win from the Alps trial, but the most important event is still to come.
Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.
The company’s plan to cut jobs and look at external deals could be a sign that it is becoming more like other big pharmas.
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
Promising mid-stage data in a third indication for efgartigimod have given the Belgian company another boost.
Bristol-Myers Squibb is ahead in a new oral class that could bring similar efficacy to current injectables for autoimmune diseases – but Pfizer seems less keen.
Competition in the CGRP migraine space has left both Teva and Amgen willing to take hits on sales to hook new patients.
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…
Galapagos needs to impress with its cystic fibrosis triplet to have a hope of catching Vertex, while Abbott needs the Coapt study of MitraClip to reach a different…